ECDC/EMEA Joint Technical Report: The bacterial challenge: time to react
There is a gap between the burden of infections due to multidrug-resistant bacteria and the development of new antibiotics to tackle the problem. This report gives an account of facts and figures that would allow reasonable predictions of the extent of this gap in the coming years and calls for a European and global strategy to address the problem urgently.One of the conclusions of the report is that there is a particular lack of new antibiotics with new targets or mechanisms of action against multidrug-resistant Gram-negative bacteria. Only two such agents with new or possibly new targets and documented activity were identified, both in early phases of development
Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA
23 Sep 2021 - This report provides an updated overview of the progress of national COVID-19 vaccination strategies in EU/EEA countries, including updates on: vaccine uptake overall and by target group; current vaccination phases and priority groups, as well as any adjustments made to priority groups during the rollout; vaccination strategies and policies in place; and the use of vaccination certificates and challenges countries face with the rollout and good practices to mitigate these challenges.
Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme: long-term care facilities, version 2.0
3 Sep 2021 - The main aim of this activity is to collect information on the severity of breakthrough COVID-19 infections in outbreaks at long-term care facilities (LTCFs) and to obtain a timely estimate of vaccine effectiveness in these settings, by SARS-CoV-2 variant and vaccine product.
Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence
22 Jul 2021 - This document provides a review of evidence on three topics of interest (effectiveness of partial vaccination, immunogenicity and effectiveness of vaccination for previously infected individuals and safety and immunogenicity of heterologous schedules) to inform ongoing decision-making in relation to national vaccination policies and strategies in the European Union and European Economic Area (EU/EEA) countries.